Panian J, Zhong C, Choi S, BA RQ, Ferrier E, Saad E, Saliby RM, Malvar C, Pal S, Ebrahimi H, Tran B, Jude E, Lalani A-K, Suarez C, De Velasco G, Kanesvaran R, Zarbá M, Chehade REH, Choueiri TK, Heng D, McKay R. 35 Efficacy of treatments post-lenvatinib in patients with advanced renal cell carcinoma (aRCC). The Oncologist. 2024;29(Supplement_1):10.1093/oncolo/oyae181.036
Marx G, Chowdhury S, Krieger L, Hovey E, Shapiro J, Tran B, Tan TH, Ng S, Woo HH. A practical guide for the use of apalutamide for non‐metastatic castration‐resistant prostate cancer in Australia. Asia-Pacific Journal of Clinical Oncology. 2024;20(4):10.1111/ajco.14054
Dholaria H, Tran B. Time to diversify: germline exome sequencing for men with testicular germ cell tumour. Translational Andrology and Urology. 2024;:10.21037/tau-24-85
Kostos L, Tran B, Azad AA. Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer. Drugs. 2024;:10.1007/s40265-024-02071-y
Conduit C, Lewin J, Hong W, Sim I, Ahmad G, Leonard M, O’Haire S, Moody M, Hutchinson AD, Lawrentschuk N, Thomas B, Dhillon HM, Tran B. Pseudoephedrine for ejaculatory dysfunction after retroperitoneal lymph node dissection in testicular cancer. BJU International. 2024;:10.1111/bju.16481
Pal SK, Tran B, Haanen JBAG, Hurwitz ME, Sacher A, Tannir NM, Budde LE, Harrison SJ, Klobuch S, Patel SS, Meza L, Dequeant M-L, Ma A, He QA, Williams LM, Keegan A, Gurary EB, Dar H, Karnik S, Guo C, Heath H, Yuen RR, Morrow PK, Agarwal N, Srour SA. CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma. Cancer Discovery. 2024;14(7):10.1158/2159-8290.cd-24-0102
Hitchen N, Shahnam A, Manoharan S, Topp M, Mileshkin L, Lim AM, Whittle JR, Luen SJ, Solomon B, Lackovic K, Desai J, Tran B. Trends in phase 1 oncology clinical trials across Australia; Analysis of ClinicalTrials.gov 2012–2022. Asia-Pacific Journal of Clinical Oncology. 2024;:10.1111/ajco.14100
Weickhardt A, Foroudi F, Lawrentschuk N, Xie J, Sidhom M, Pal A, Grimison P, Zhang A, Ng S, Tang C, Hovey E, Chen C, Hruby G, Guminski A, McJannett M, Conduit C, Tran B, Davis ID, Hayne D. Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502). European Urology Oncology. 2024;7(3):10.1016/j.euo.2023.09.011
Wahlroos S, Teng C, Tran B, Voskoboynik M, Gan HK, Spencer A, Kudva A, Song M, Lynch K, Yu Z, Desai J, Lemech CR. Results of a first-in-human, dose-escalation phase 1 study of the ERK1/2 inhibitor ATG-017 in patients with advanced solid tumors.Journal of Clinical Oncology. 2024;42(16_suppl):10.1200/jco.2024.42.16_suppl.e15114
Panian J, Zhong C, Choi S, Quinn R, Ferrier E, Saad E, Saliby RM, Malvar C, Pal SK, Ebrahimi H, Tran B, Weickhardt AJ, Lalani A-KA, Suárez C, de Velasco G, Kanesvaran R, Zarba M, CHOUEIRI TK, Heng DYC, McKay RR. Efficacy of post-lenvatinib treatments in patients (pts) with advanced renal cell carcinoma (aRCC).Journal of Clinical Oncology. 2024;42(16_suppl):10.1200/jco.2024.42.16_suppl.4538
